NZ604478A - Fused heterocyclic compounds as ion channel modulators - Google Patents
Fused heterocyclic compounds as ion channel modulatorsInfo
- Publication number
- NZ604478A NZ604478A NZ604478A NZ60447811A NZ604478A NZ 604478 A NZ604478 A NZ 604478A NZ 604478 A NZ604478 A NZ 604478A NZ 60447811 A NZ60447811 A NZ 60447811A NZ 604478 A NZ604478 A NZ 604478A
- Authority
- NZ
- New Zealand
- Prior art keywords
- heart failure
- compounds
- angina
- disease
- diabetes
- Prior art date
Links
- 102000004310 Ion Channels Human genes 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 208000028867 ischemia Diseases 0.000 abstract 2
- -1 quinolonyl Chemical group 0.000 abstract 2
- LJRXNXBFJXXRNQ-UHFFFAOYSA-N 2h-[1,2,4]triazolo[4,3-a]pyridin-3-one Chemical class C1=CC=CN2C(=O)NN=C21 LJRXNXBFJXXRNQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002388 Angina unstable Diseases 0.000 abstract 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 abstract 1
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 1
- 206010010904 Convulsion Diseases 0.000 abstract 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 abstract 1
- 208000003037 Diastolic Heart Failure Diseases 0.000 abstract 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
- 206010022562 Intermittent claudication Diseases 0.000 abstract 1
- 206010033799 Paralysis Diseases 0.000 abstract 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 108010052164 Sodium Channels Proteins 0.000 abstract 1
- 102000018674 Sodium Channels Human genes 0.000 abstract 1
- 208000007718 Stable Angina Diseases 0.000 abstract 1
- 208000008253 Systolic Heart Failure Diseases 0.000 abstract 1
- 208000007814 Unstable Angina Diseases 0.000 abstract 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000001746 atrial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 abstract 1
- 208000021156 intermittent vascular claudication Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 208000004296 neuralgia Diseases 0.000 abstract 1
- 208000021722 neuropathic pain Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 230000000306 recurrent effect Effects 0.000 abstract 1
- 229910052708 sodium Inorganic materials 0.000 abstract 1
- 239000011734 sodium Substances 0.000 abstract 1
- 125000001113 thiadiazolyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36105610P | 2010-07-02 | 2010-07-02 | |
| PCT/US2011/042700 WO2012003392A1 (en) | 2010-07-02 | 2011-06-30 | Fused heterocyclic compounds as ion channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ604478A true NZ604478A (en) | 2014-12-24 |
Family
ID=44338422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ604478A NZ604478A (en) | 2010-07-02 | 2011-06-30 | Fused heterocyclic compounds as ion channel modulators |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8703759B2 (https=) |
| EP (1) | EP2588197B1 (https=) |
| JP (2) | JP5858586B2 (https=) |
| KR (1) | KR101911560B1 (https=) |
| CN (1) | CN103096977B (https=) |
| AU (1) | AU2011272787B2 (https=) |
| BR (1) | BR112012033402A2 (https=) |
| CA (1) | CA2802288C (https=) |
| EA (1) | EA026385B9 (https=) |
| ES (1) | ES2529119T3 (https=) |
| IL (1) | IL223724A (https=) |
| MX (1) | MX2012015096A (https=) |
| NZ (1) | NZ604478A (https=) |
| PT (1) | PT2588197E (https=) |
| TW (1) | TWI537266B (https=) |
| WO (1) | WO2012003392A1 (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2642586T3 (es) * | 2009-07-27 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| KR20140033377A (ko) | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| US9266881B2 (en) * | 2011-11-14 | 2016-02-23 | Merck Sharp & Dohme Corp. | Triazolopyridinone PDE10 inhibitors |
| HK1201455A1 (en) | 2012-01-27 | 2015-09-04 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| US9550775B2 (en) * | 2013-03-14 | 2017-01-24 | Genentech, Inc. | Substituted triazolopyridines and methods of use thereof |
| JP6602779B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| EP3105218B1 (en) | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| WO2015192760A1 (zh) * | 2014-06-17 | 2015-12-23 | 南京明德新药研发股份有限公司 | 作为pi3k抑制剂的吡啶并［1，2-a］嘧啶酮类似物 |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| CN105001217A (zh) * | 2015-06-16 | 2015-10-28 | 浙江工业大学 | 一种[1,2,4]三唑[4,3-α]吡啶-3(2H)-酮衍生物的制备方法 |
| MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| US20170081323A1 (en) | 2015-09-18 | 2017-03-23 | F. Hoffmann-La Roche Ag | Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease |
| TWI833686B (zh) | 2016-04-22 | 2024-03-01 | 美商英塞特公司 | Lsd1 抑制劑之調配物 |
| DK3548033T3 (da) | 2016-11-28 | 2024-07-15 | Praxis Prec Medicines Inc | Forbindelser og deres fremgangsmåde til anvendelse |
| WO2018098491A1 (en) | 2016-11-28 | 2018-05-31 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| JP7190906B2 (ja) | 2017-01-24 | 2022-12-16 | 住友化学株式会社 | 縮合複素環化合物及びそれを含有する組成物 |
| US11492345B2 (en) | 2017-02-13 | 2022-11-08 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2018187480A1 (en) | 2017-04-04 | 2018-10-11 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019043635A1 (en) | 2017-09-01 | 2019-03-07 | Richter Gedeon Nyrt. | COMPOUNDS INHIBITING THE ACTIVITY OF D-AMINO ACID OXIDASE |
| MX2020012838A (es) | 2018-05-30 | 2021-07-16 | Praxis Prec Medicines Inc | Moduladores de los canales ionicos. |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| EA202092908A1 (ru) | 2018-09-28 | 2021-05-14 | Праксис Пресижн Медсинз, Инк. | Модуляторы ионных каналов |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11767325B2 (en) | 2019-11-26 | 2023-09-26 | Praxis Precision Medicines, Inc. | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators |
| PE20221280A1 (es) | 2019-11-27 | 2022-09-05 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos |
| KR20250005348A (ko) | 2022-04-26 | 2025-01-09 | 프락시스 프리시젼 메디신즈, 인크. | 신경 장애의 치료 |
| GB202216960D0 (en) * | 2022-11-14 | 2022-12-28 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (166)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4230705A (en) | 1976-09-22 | 1980-10-28 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety |
| US4242515A (en) | 1979-03-28 | 1980-12-30 | American Cyanamid Company | Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines |
| US4244953A (en) | 1979-10-24 | 1981-01-13 | American Cyanamid Company | Substituted 6-phenyl-5,6,7,8-tetrahydro-1,2,4-triazolo-[4,3-a]pyridines |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4812565A (en) | 1982-09-30 | 1989-03-14 | A. H. Robins Company, Incorporated | Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US4654343A (en) | 1985-10-31 | 1987-03-31 | American Cyanamid Company | N-substituted-N[3-(1,2,4-triazolo[4,3-b]pyridazin-6-yl)phenyl]alkanamides, carbamates and ureas |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4746655A (en) | 1987-06-10 | 1988-05-24 | A. H. Robins Company, Incorporated | Fused aromatic-spiropiperidine oxazepinones(and thiones) |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| DE4010488A1 (de) | 1990-03-31 | 1991-10-02 | Hoechst Ag | Benzoxazinderivate, verfahren zu ihrer herstellung und ihre verwendung zum behandeln oder zur prophylaxe von krankheiten |
| CA2044564A1 (en) | 1990-06-28 | 1991-12-29 | Quirico Branca | Amino acid derivatives |
| CN1060467A (zh) | 1990-09-25 | 1992-04-22 | 武田药品工业株式会社 | 1，3-苯并嗪衍生物、其生产方法和用途 |
| JPH04209692A (ja) | 1990-12-03 | 1992-07-31 | Asahi Glass Co Ltd | フォトクロミック材料 |
| US5246948A (en) | 1991-05-10 | 1993-09-21 | Takeda Chemical Industries, Ltd. | Pyridine derivatives, their production and use |
| US5939412A (en) | 1992-06-26 | 1999-08-17 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| US5693636A (en) | 1991-06-28 | 1997-12-02 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| US5250679A (en) | 1991-10-18 | 1993-10-05 | Genentech, Inc. | Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor |
| US5674863A (en) | 1991-10-18 | 1997-10-07 | Genentech, Inc. | Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH06107647A (ja) | 1992-08-12 | 1994-04-19 | Takeda Chem Ind Ltd | １，３−ベンゾオキサジン誘導体の製造法 |
| US5442055A (en) | 1992-11-13 | 1995-08-15 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| US6011150A (en) | 1992-11-13 | 2000-01-04 | Tanabe Seiyaku Co., Ltd. | Azetidinone compound and process for preparation thereof |
| GB9225860D0 (en) | 1992-12-11 | 1993-02-03 | Smithkline Beecham Plc | Novel treatment |
| GB9226302D0 (en) | 1992-12-17 | 1993-02-10 | Smithkline Beecham Plc | Pharmaceuticals |
| US5550229A (en) | 1993-06-23 | 1996-08-27 | Tanabe Seiyaku Co., Ltd. | Alkylation process for preparing azetidinone compound and starting compound therefor |
| DE19526173A1 (de) | 1995-07-18 | 1997-01-30 | Hoechst Ag | Polyfullerenaddukte, Verfahren zu ihrer regioselektiven Herstellung und deren Verwendung |
| JPH09157262A (ja) | 1995-12-08 | 1997-06-17 | Tanabe Seiyaku Co Ltd | アゼチジノン誘導体及びその合成中間体の製法 |
| GB9619492D0 (en) | 1996-09-18 | 1996-10-30 | Smithkline Beecham Plc | Novel treatment |
| EP0975614A1 (en) | 1997-04-18 | 2000-02-02 | Smithkline Beecham Plc | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
| JP3964053B2 (ja) | 1997-07-10 | 2007-08-22 | 三井化学株式会社 | 遷移金属化合物からなるオレフィン重合用触媒ならびに重合方法 |
| WO1999013038A1 (en) | 1997-09-08 | 1999-03-18 | Unilever N.V. | Method for enhancing the activity of an enzyme |
| WO1999041246A1 (en) | 1998-02-11 | 1999-08-19 | Du Pont Pharmaceuticals Company | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
| CN1293665A (zh) | 1998-02-18 | 2001-05-02 | 神经研究公司 | 新化合物及其用作阳性ampa受体调节剂 |
| WO2000023451A1 (en) | 1998-10-21 | 2000-04-27 | Novo Nordisk A/S | New compounds, their preparation and use |
| AU4145200A (en) | 1999-05-07 | 2000-11-21 | Takeda Chemical Industries Ltd. | Cyclic compounds and uses thereof |
| AU7072200A (en) | 1999-08-27 | 2001-03-26 | Procter & Gamble Company, The | Fast-acting formulation components, compositions and laundry methods employing same |
| TR200200457T2 (tr) | 1999-08-27 | 2002-07-22 | The Procter & Gamble Company | Zitteriyonik formülasyon bileşenleri kullanılan renklerin solmasını önleyici çamaşır yöntemleri. |
| EP1206517A1 (en) | 1999-08-27 | 2002-05-22 | The Procter & Gamble Company | Color safe laundry methods employing cationic formulation components |
| EP1206513A2 (en) | 1999-08-27 | 2002-05-22 | The Procter & Gamble Company | Controlled availability of formulation components, compositions and laundry methods employing same |
| JP2003508587A (ja) | 1999-08-27 | 2003-03-04 | ザ、プロクター、エンド、ギャンブル、カンパニー | 安定性増強配合成分、これを用いた組成物および洗濯方法 |
| TR200200471T2 (tr) | 1999-08-27 | 2002-05-21 | The Procter & Gamble Company | Kararlı formülasyon komponentleri, bunların kullanıldığı terkipler ve çamaşır yıkama metodları |
| EP1210332B1 (en) | 1999-08-27 | 2006-05-31 | The Procter & Gamble Company | Bleach boosting components, compositions and laundry methods |
| EP1286994A1 (en) | 2000-05-15 | 2003-03-05 | Darwin Discovery Limited | Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity |
| CZ2003284A3 (cs) | 2000-08-01 | 2003-09-17 | Ono Pharmaceutical Co., Ltd. | 3,4-Dihydroisochinolinový derivát a farmaceutické činidlo obsahující tento derivát jako účinnou složku |
| JP2004521079A (ja) | 2000-08-29 | 2004-07-15 | ファルマシア・コーポレーション | アルファーｖベータ３アンタゴニストとして有用な二環式環系を含有する化合物 |
| US6822664B2 (en) * | 2000-10-11 | 2004-11-23 | Microsoft Corporation | Browser navigation for devices with a limited input system |
| JP2002205992A (ja) | 2000-11-08 | 2002-07-23 | Takeda Chem Ind Ltd | 二環式トリアゾロン誘導体およびそれを含有する除草剤 |
| EP1354602B1 (en) | 2000-12-26 | 2006-10-04 | Sankyo Company, Limited | Medicinal compositions containing diuretic and insulin resistance-improving agent |
| HUP0303415A2 (hu) | 2001-03-09 | 2004-01-28 | Pfizer Products Inc. | Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények |
| US6998408B2 (en) | 2001-03-23 | 2006-02-14 | Bristol-Myers Squibb Pharma Company | 6-5, 6-6, or 6-7 Heterobicycles as factor Xa inhibitors |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2005089298A (ja) | 2001-09-18 | 2005-04-07 | Japan Tobacco Inc | ナフタレン化合物及びその医薬用途 |
| US7196108B2 (en) | 2002-03-08 | 2007-03-27 | Incyte San Diego Inc. | Bicyclic heterocycles for the treatment of diabetes and other diseases |
| JP2003277384A (ja) | 2002-03-26 | 2003-10-02 | Kyorin Pharmaceut Co Ltd | 縮合ニ環式ピリジン誘導体 |
| JP2003321461A (ja) | 2002-04-25 | 2003-11-11 | Kyorin Pharmaceut Co Ltd | 縮合ビフェニル誘導体 |
| CA2497658A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Chromone derivatives as matrix metalloproteinase inhibitors |
| PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
| US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
| AU2003262073A1 (en) | 2002-09-20 | 2004-04-08 | Tsumura And Co. | Antitussives |
| US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| GB0223730D0 (en) * | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
| AU2003285946A1 (en) | 2002-10-22 | 2004-05-13 | The Trustees Of The University Of Pennsylvania | Identification of antimycobacterial targets and the inhibition thereof as a treatment for infectious diseases |
| CN100430386C (zh) * | 2002-11-07 | 2008-11-05 | 默克公司 | 苯丙氨酸衍生物作为二肽基肽酶抑制剂用于治疗或预防糖尿病 |
| CA2504735C (en) | 2002-11-07 | 2009-06-23 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| EP1592464A4 (en) | 2003-01-13 | 2011-03-09 | Cortex Pharma Inc | METHOD OF TREATING COGNITIVE DECLINE FROM LACK OF SLEEP AND STRESS |
| MY142651A (en) | 2003-03-18 | 2010-12-15 | Merck Sharp & Dohme | Biaryl substituted triazoles as sodium channel blockers |
| DE10317526A1 (de) | 2003-04-16 | 2004-11-04 | Degussa Ag | Verfahren zum Delignifizieren von ligninhaltigen Faserstoffen |
| AU2004232939A1 (en) | 2003-04-17 | 2004-11-04 | Merck Sharp & Dohme Corp. | Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity |
| MXPA05010174A (es) | 2003-04-25 | 2005-11-08 | Lundbeck & Co As H | Derivados de indol e indolina sustituidos. |
| CN1816530A (zh) | 2003-07-01 | 2006-08-09 | 麦克公司 | 用于治疗高眼压症的眼用组合物 |
| CN1894222A (zh) | 2003-08-05 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 作为电压门控离子通道抑制剂的稠合嘧啶化合物 |
| US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| BRPI0417674A (pt) | 2003-12-18 | 2007-03-20 | Pfizer Prod Inc | método para tratar a inflamação aguda em animais, com inibidores de quinase map p38 |
| US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
| WO2006002470A1 (en) | 2004-06-30 | 2006-01-12 | Monash University | Chiral ligands for asymmetric catalysis |
| JP2006063064A (ja) | 2004-07-27 | 2006-03-09 | Takeda Chem Ind Ltd | 受容体作動剤 |
| JP2007297283A (ja) | 2004-07-28 | 2007-11-15 | Santen Pharmaceut Co Ltd | 新規桂皮酸関連化合物 |
| EP1784390A2 (en) | 2004-08-13 | 2007-05-16 | Amgen Inc. | Substituted benzofused heterocycles |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| EP1784188B1 (en) | 2004-08-23 | 2010-07-14 | Merck Sharp & Dohme Corp. | Fused triazole derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US7750010B2 (en) | 2004-09-13 | 2010-07-06 | Merck Sharp & Dohme Corp. | Tricyclic anilide spirohydantion CGRP receptor antagonists |
| WO2006048727A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Products Inc. | Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor |
| US7579348B2 (en) | 2005-02-25 | 2009-08-25 | Pgxhealth, Llc | Derivatives of 8-substituted xanthines |
| TW200643015A (en) | 2005-03-11 | 2006-12-16 | Akzo Nobel Nv | 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| BRPI0611948A2 (pt) | 2005-06-17 | 2010-10-13 | Wyeth Corp | compostos úteis como inibidores de serotonina e agonistas de antagonista de 5-ht1a |
| US7632837B2 (en) * | 2005-06-17 | 2009-12-15 | Bristol-Myers Squibb Company | Bicyclic heterocycles as cannabinoid-1 receptor modulators |
| TW200726765A (en) * | 2005-06-17 | 2007-07-16 | Bristol Myers Squibb Co | Triazolopyridine cannabinoid receptor 1 antagonists |
| WO2007004028A2 (en) | 2005-06-30 | 2007-01-11 | Ranbaxy Laboratories Limited | Processes for the preparation of penems and its intermediate |
| WO2007023750A1 (ja) | 2005-08-26 | 2007-03-01 | National University Corporation University Of Toyama | 乾燥羊膜及び羊膜の乾燥処理方法 |
| CA2621255A1 (en) | 2005-09-21 | 2007-04-05 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| US7482360B2 (en) | 2005-09-23 | 2009-01-27 | Schering Corporation | Fused tetracyclic mGluR1 antagonists as therapeutic agents |
| US20090022694A1 (en) | 2005-10-18 | 2009-01-22 | Distefano Peter | Sirt1 inhibition |
| TW200804290A (en) | 2005-11-15 | 2008-01-16 | Astrazeneca Ab | Compounds and uses thereof |
| WO2007061677A2 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirolactam aryl cgrp receptor antagonists |
| JP2009515976A (ja) | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロラクタム二環式ｃｇｒｐ受容体アンタゴニスト |
| TW200734342A (en) | 2005-12-15 | 2007-09-16 | Astrazeneca Ab | New compounds for the treatment of cardiac arrhythmias |
| CN101330914A (zh) | 2005-12-16 | 2008-12-24 | 爱尔康公司 | 使用alk5调节剂控制眼内压 |
| US8013073B2 (en) | 2005-12-30 | 2011-09-06 | Chevron Oronite Company Llc | Method for preparing polyolefins containing vinylidine end groups using nonaromatic heterocyclic compounds |
| MX2008012617A (es) | 2006-03-31 | 2008-10-10 | Novartis Ag | Compuestos organicos. |
| WO2007146284A2 (en) | 2006-06-12 | 2007-12-21 | Vertex Pharmaceuticals Incorporated | Thienopyrimidines useful as modulators of ion channels |
| WO2008005338A1 (en) | 2006-06-29 | 2008-01-10 | Arena Pharmaceuticals, Inc. | Modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| EP2038272B8 (en) | 2006-06-30 | 2013-10-23 | Sunesis Pharmaceuticals, Inc. | Pyridinonyl pdk1 inhibitors |
| US20090318412A1 (en) | 2006-07-11 | 2009-12-24 | Takahiro Matsumoto | Tricyclic heterocyclic compound and use thereof |
| AU2007272009A1 (en) | 2006-07-12 | 2008-01-17 | Syngenta Limited | Triazolopyridine derivatives as herbicides |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8217177B2 (en) | 2006-07-14 | 2012-07-10 | Amgen Inc. | Fused heterocyclic derivatives and methods of use |
| EP2068869A4 (en) | 2006-10-06 | 2011-05-25 | Abbott Lab | NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE |
| WO2008118141A2 (en) | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
| ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
| CN105481788A (zh) | 2006-10-28 | 2016-04-13 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
| WO2008053913A1 (en) | 2006-11-02 | 2008-05-08 | Shionogi & Co., Ltd. | Sulfonylurea derivative capable of selectively inhibiting mmp-13 |
| CA2670651A1 (en) | 2006-12-21 | 2008-07-03 | Cv Therapeutics, Inc. | Reduction of cardiovascular symptoms |
| US8076350B2 (en) | 2006-12-22 | 2011-12-13 | Abbott Laboratories | Spirocyclic azaadamantane derivatives and methods of use |
| AR065081A1 (es) | 2007-01-29 | 2009-05-13 | Xenon Pharmaceuticals Inc | Compuestos de quinazolinona y pirimidona fusionados y composicion farmaceutica |
| EP2123644B1 (en) | 2007-03-07 | 2014-12-17 | Takeda Pharmaceutical Company Limited | Benzoxazepine derivatives and use thereof |
| GB0706072D0 (en) | 2007-03-28 | 2007-05-09 | Sterix Ltd | Compound |
| WO2008134553A1 (en) | 2007-04-26 | 2008-11-06 | Xenon Pharmaceuticals Inc. | Methods of using bicyclic compounds in treating sodium channel-mediated diseases |
| WO2008144483A2 (en) | 2007-05-18 | 2008-11-27 | Armgo Pharma, Inc. | Agents for treating disorders involving modulation of ryanodine receptors |
| WO2009005675A1 (en) | 2007-06-28 | 2009-01-08 | Abbott Laboratories | Novel triazolopyridazines |
| US20110263569A1 (en) | 2007-08-22 | 2011-10-27 | President And Fellows Of Harvard College | Ryanodine channel binders and uses thereof |
| WO2009036144A1 (en) | 2007-09-12 | 2009-03-19 | Wyeth | Isoquinolinyl and isoindolinyl derivatives as histamine-3 antagonists |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US8293763B2 (en) | 2007-12-19 | 2012-10-23 | Genentech, Inc. | 8-anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents |
| EP2231669A1 (en) | 2008-01-09 | 2010-09-29 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphodiesterase inhibitors |
| CA2713521A1 (en) | 2008-02-06 | 2009-08-13 | Gilead Palo Alto, Inc. | Use of ranolazine for treating pain |
| KR20100124262A (ko) * | 2008-02-13 | 2010-11-26 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 비시클로아민 유도체 |
| WO2009137462A2 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Methods for treating cognitive disorders using inhibitors of histone deacetylase |
| WO2009137499A1 (en) | 2008-05-05 | 2009-11-12 | Envivo Pharmaceuticals, Inc. | Inhibitors of histone deacetylase |
| DE102008024182A1 (de) | 2008-05-19 | 2009-11-26 | Merck Patent Gmbh | Verbindungen für organische elektronische Vorrichtung |
| EP2297140A4 (en) * | 2008-06-06 | 2012-05-02 | Abbott Lab | NOVEL 1,2,4-OXADIAZOLE COMPOUNDS AND METHODS OF USE |
| WO2009153589A1 (en) | 2008-06-17 | 2009-12-23 | Astrazeneca Ab | Pyridine compounds |
| CA2730377C (en) | 2008-07-11 | 2017-09-19 | Neumedics | Tetracycline derivatives with reduced antibiotic activity and neuroprotective benefits |
| JP5303561B2 (ja) | 2008-08-12 | 2013-10-02 | 日本曹達株式会社 | 含窒素ヘテロ環誘導体および農園芸用殺菌剤 |
| CN102186812A (zh) | 2008-08-18 | 2011-09-14 | 宇部兴产株式会社 | 制备氟烷基芳基亚磺酰基化合物及其氟化的化合物的方法 |
| EP2337559A2 (en) | 2008-09-04 | 2011-06-29 | Gilead Sciences, Inc. | Method of treating atrial fibrillation |
| WO2010053757A1 (en) | 2008-10-29 | 2010-05-14 | Gilead Palo Alto, Inc. | 2 -oxoquinoxalin blockers of the late sodium channel |
| US8389500B2 (en) | 2008-10-30 | 2013-03-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| EP2373653B1 (en) | 2008-12-05 | 2014-04-02 | F. Hoffmann-La Roche AG | Pyrrolopyrazinyl urea kinase inhibitors |
| JP5752601B2 (ja) | 2008-12-08 | 2015-07-22 | ブイエム ファーマ エルエルシー | タンパク質受容体チロシンキナーゼ阻害薬の組成物 |
| EP2373645A4 (en) | 2008-12-08 | 2012-05-02 | Sirtris Pharmaceuticals Inc | ISOINDOLINONE AND RELATED ANALOGUES AS SIRTUIN MODULATORS |
| FR2943342B1 (fr) | 2009-03-20 | 2011-03-04 | Servier Lab | Nouveaux derives de benzothiadiazepines,leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| ES2642586T3 (es) | 2009-07-27 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos heterocíclicos condensados como moduladores de canales iónicos |
| MY160064A (en) | 2009-09-28 | 2017-02-15 | Hoffmann La Roche | Benzoxazepin pi3k inhibitor compounds and methods of use |
| US20110152246A1 (en) | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| TWI508726B (zh) | 2009-12-21 | 2015-11-21 | Gilead Sciences Inc | 治療心房纖維性顫動之方法 |
| EP2588197B1 (en) | 2010-07-02 | 2014-11-05 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| WO2012019071A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Methods of preventing and treating sarcopenia |
| WO2012019076A1 (en) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for preventing and treating cardiac ischemia/reperfusion injury |
| WO2012037105A1 (en) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Methods of treating, ameliorating or preventing stress-induced neuronal disorders and diseases |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| EP2643316A2 (en) | 2010-11-24 | 2013-10-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of p13k/mtor and methods of their use and manufacture |
| KR20140033377A (ko) | 2011-05-10 | 2014-03-18 | 길리애드 사이언시즈, 인코포레이티드 | 나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물 |
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| NO3175985T3 (https=) | 2011-07-01 | 2018-04-28 | ||
| HK1201455A1 (en) | 2012-01-27 | 2015-09-04 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
-
2011
- 2011-06-30 EP EP11732540.7A patent/EP2588197B1/en active Active
- 2011-06-30 JP JP2013518741A patent/JP5858586B2/ja not_active Expired - Fee Related
- 2011-06-30 AU AU2011272787A patent/AU2011272787B2/en not_active Ceased
- 2011-06-30 CA CA2802288A patent/CA2802288C/en not_active Expired - Fee Related
- 2011-06-30 ES ES11732540.7T patent/ES2529119T3/es active Active
- 2011-06-30 US US13/174,587 patent/US8703759B2/en active Active
- 2011-06-30 MX MX2012015096A patent/MX2012015096A/es active IP Right Grant
- 2011-06-30 EA EA201291272A patent/EA026385B9/ru not_active IP Right Cessation
- 2011-06-30 KR KR1020137001153A patent/KR101911560B1/ko not_active Expired - Fee Related
- 2011-06-30 NZ NZ604478A patent/NZ604478A/en not_active IP Right Cessation
- 2011-06-30 WO PCT/US2011/042700 patent/WO2012003392A1/en not_active Ceased
- 2011-06-30 PT PT117325407T patent/PT2588197E/pt unknown
- 2011-06-30 BR BR112012033402A patent/BR112012033402A2/pt not_active Application Discontinuation
- 2011-06-30 CN CN201180042654.5A patent/CN103096977B/zh not_active Expired - Fee Related
- 2011-07-01 TW TW100123352A patent/TWI537266B/zh not_active IP Right Cessation
-
2012
- 2012-12-18 IL IL223724A patent/IL223724A/en active IP Right Grant
-
2014
- 2014-03-17 US US14/217,011 patent/US9079901B2/en active Active
-
2015
- 2015-11-18 JP JP2015225781A patent/JP2016029107A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP5858586B2 (ja) | 2016-02-10 |
| EA201291272A1 (ru) | 2013-12-30 |
| CN103096977B (zh) | 2017-02-15 |
| KR101911560B1 (ko) | 2018-10-24 |
| US20150080370A1 (en) | 2015-03-19 |
| ES2529119T3 (es) | 2015-02-17 |
| IL223724A (en) | 2016-06-30 |
| EP2588197B1 (en) | 2014-11-05 |
| EA026385B1 (ru) | 2017-04-28 |
| CA2802288A1 (en) | 2012-01-05 |
| AU2011272787A1 (en) | 2013-01-10 |
| CN103096977A (zh) | 2013-05-08 |
| TW201215608A (en) | 2012-04-16 |
| EP2588197A1 (en) | 2013-05-08 |
| PT2588197E (pt) | 2015-02-09 |
| MX2012015096A (es) | 2013-05-28 |
| CA2802288C (en) | 2018-08-21 |
| EA026385B9 (ru) | 2017-08-31 |
| HK1184092A1 (en) | 2014-01-17 |
| US9079901B2 (en) | 2015-07-14 |
| US8703759B2 (en) | 2014-04-22 |
| AU2011272787B2 (en) | 2015-06-18 |
| BR112012033402A2 (pt) | 2017-01-24 |
| US20120010192A1 (en) | 2012-01-12 |
| JP2013535423A (ja) | 2013-09-12 |
| TWI537266B (zh) | 2016-06-11 |
| JP2016029107A (ja) | 2016-03-03 |
| WO2012003392A1 (en) | 2012-01-05 |
| KR20130043158A (ko) | 2013-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ604478A (en) | Fused heterocyclic compounds as ion channel modulators | |
| NZ716245A (en) | Fused benzoxazepinones as ion channel modulators | |
| CN104902895B (zh) | 可用作用于治疗增生性疾病的激酶抑制剂的二氢萘啶和相关化合物 | |
| JP6078640B2 (ja) | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 | |
| AU2003250159B2 (en) | Acylated arylcycloalkylamines and their use as pharmaceuticals | |
| JP7241556B2 (ja) | 含窒素複素環アミド化合物及びその医薬用途 | |
| EP3181557A1 (en) | Carboxylic acid compound, method for preparation thereof, and use thereof | |
| IL159897A0 (en) | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | |
| CN112028877B (zh) | 烷氧吡啶酮化合物及其制备方法和用途 | |
| AU2016233618A1 (en) | Triazolyl pyrimidinone compounds as PDE2 inhibitors | |
| AU2021283577A1 (en) | Novel thyroid hormone β receptor agonist | |
| HUE034254T2 (en) | Substituted condensed pyrimidine compounds | |
| JP7021405B2 (ja) | イソクエン酸脱水素酵素（ｉｄｈ）阻害剤 | |
| EP3693358A1 (en) | Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof | |
| CN106632245A (zh) | 氮取代基苯基吡唑类黄嘌呤氧化还原酶抑制剂及制备与应用 | |
| CA2523196A1 (en) | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | |
| EP2841423B1 (en) | Method for producing 5-(difluoromethyl)pyrazine-2-carboxilic acid and production intermediate thereof | |
| CN107033149B (zh) | 一种dpp-4酶抑制剂及其制备和应用 | |
| AU2006218037B2 (en) | 2-sulfinyl- and 2-sulfonyl-substituted imidazole derivatives and their use as cytokine inhibitors | |
| EP2919782B1 (en) | Secondary alcohol subsituted triazoles as pde10 inhibitors | |
| CA3243368A1 (en) | COMPOUND FOR REGULATING AND CONTROLLING THE ACTIVITY OF 15-PGDH AND ITS PREPARATION PROCESS | |
| ES2411095T3 (es) | Uso de lactoles de atorvastatina como medicamentos | |
| EP2578588A1 (en) | Novel 1,4-diazepam pde-5 inhibitor derivatives | |
| ATE365737T1 (de) | Substituierte piperazinverbindungen undderen verwendung als fettsuureoxidationsinhibitoren | |
| CN108884048B (zh) | 一种吡啶酮类衍生物的制备方法及其中间体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2016 BY COMPUTER PACKAGES INC Effective date: 20150602 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2017 BY COMPUTER PACKAGES INC Effective date: 20160601 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2018 BY COMPUTER PACKAGES INC Effective date: 20170531 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 JUN 2019 BY COMPUTER PACKAGES INC Effective date: 20180531 |
|
| LAPS | Patent lapsed |